Document Detail


The harlequin color change and association with prostaglandin E1.
MedLine Citation:
PMID:  15461766     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The harlequin color change is an unusual cutaneous phenomenon observed in newborn infants as transient, benign episodes of a sharply demarcated erythema on half of the infant, with simultaneous contralateral blanching. In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association. The benign, self-limited nature of the color change mandates that prostaglandin E1 not be discontinued for this reason. The entity is likely more common than the paucity of reports in the world literature suggests, and all physicians should recognize its graphic appearance to avoid unnecessary exposure to agents in an effort to treat it.
Authors:
Jaggi Rao; Morag E Campbell; Alfons Krol
Related Documents :
18683186 - A procedure for the measurement of infant skin conductance and its initial validation u...
8479246 - The single-pass perfused rabbit ear as a model for studying percutaneous absorption of ...
8491876 - Focal dermal hypoplasia: four cases with widely varying presentations.
7212726 - Annular erythema of infancy.
18811926 - Born in bradford, a cohort study of babies born in bradford, and their parents: protoco...
3723256 - Risk factors for developing and dying from necrotizing enterocolitis.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Pediatric dermatology     Volume:  21     ISSN:  0736-8046     ISO Abbreviation:  Pediatr Dermatol     Publication Date:    2004 Sep-Oct
Date Detail:
Created Date:  2004-10-05     Completed Date:  2005-01-24     Revised Date:  2009-03-03    
Medline Journal Info:
Nlm Unique ID:  8406799     Medline TA:  Pediatr Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  573-6     Citation Subset:  IM    
Affiliation:
Division of Dermatology and Cutaneous Sciences, University of Alberta, Edmonton, Alberta, Canada. jrao@ualberta.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alprostadil / administration & dosage,  adverse effects*
Diagnosis, Differential
Female
Heart Defects, Congenital / complications*,  drug therapy,  surgery
Heart Septal Defects, Ventricular / complications,  drug therapy,  surgery
Humans
Infant, Newborn
Infusions, Intravenous
Pigmentation Disorders / chemically induced,  diagnosis*,  pathology
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects*
Pulmonary Atresia / complications,  drug therapy,  surgery
Transposition of Great Vessels / complications,  drug therapy,  surgery
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutation in the ED1 gene, Ala349Thr, in a Korean patient with X-linked hypohidrotic ectodermal dyspl...
Next Document:  Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatiti...